Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) was upgraded by equities researchers at Mizuho from an “underperform” rating to a “neutral” rating in a report issued on Friday, Marketbeat.com reports. The firm currently has a $15.00 target price on the specialty pharmaceutical company’s stock, up from their prior target price of $10.00. Mizuho’s target price would suggest a potential downside of 2.85% from the stock’s previous close.
VRX has been the subject of a number of other reports. Deutsche Bank set a $20.00 target price on Valeant Pharmaceuticals International and gave the company a “hold” rating in a research note on Wednesday, February 21st. Cantor Fitzgerald set a $25.00 price objective on Valeant Pharmaceuticals International and gave the stock a “buy” rating in a research report on Wednesday, February 28th. Wells Fargo reaffirmed a “sell” rating on shares of Valeant Pharmaceuticals International in a research report on Monday, March 12th. ValuEngine raised Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating in a research report on Tuesday, December 12th. Finally, Zacks Investment Research cut Valeant Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research report on Saturday, January 13th. Five analysts have rated the stock with a sell rating, twelve have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $18.56.
NYSE:VRX opened at $15.44 on Friday. Valeant Pharmaceuticals International has a 1 year low of $8.31 and a 1 year high of $24.43. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 4.25. The stock has a market capitalization of $5,508.19, a price-to-earnings ratio of 4.03, a price-to-earnings-growth ratio of 0.33 and a beta of -0.32.
In related news, Director Schutter Richard U. De purchased 10,000 shares of Valeant Pharmaceuticals International stock in a transaction that occurred on Thursday, March 8th. The stock was purchased at an average cost of $15.34 per share, with a total value of $153,400.00. Following the completion of the transaction, the director now owns 106,062 shares of the company’s stock, valued at approximately $1,626,991.08. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director John Paulson purchased 7,066,629 shares of Valeant Pharmaceuticals International stock in a transaction that occurred on Tuesday, March 6th. The shares were bought at an average cost of $15.40 per share, with a total value of $108,826,086.60. The disclosure for this purchase can be found here. Insiders have purchased 7,121,629 shares of company stock valued at $109,702,487 over the last three months. Insiders own 5.87% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of VRX. Renaissance Technologies LLC boosted its position in Valeant Pharmaceuticals International by 122.8% during the fourth quarter. Renaissance Technologies LLC now owns 10,651,189 shares of the specialty pharmaceutical company’s stock valued at $221,332,000 after purchasing an additional 5,870,689 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Valeant Pharmaceuticals International by 327.6% in the third quarter. Dimensional Fund Advisors LP now owns 4,472,185 shares of the specialty pharmaceutical company’s stock valued at $64,086,000 after buying an additional 3,426,410 shares during the period. Two Sigma Investments LP bought a new stake in Valeant Pharmaceuticals International in the fourth quarter valued at approximately $57,221,000. Two Sigma Advisers LP raised its stake in Valeant Pharmaceuticals International by 7,294.2% in the fourth quarter. Two Sigma Advisers LP now owns 1,428,418 shares of the specialty pharmaceutical company’s stock valued at $29,683,000 after buying an additional 1,409,100 shares during the period. Finally, Schroder Investment Management Group raised its stake in Valeant Pharmaceuticals International by 2,951.5% in the fourth quarter. Schroder Investment Management Group now owns 1,113,800 shares of the specialty pharmaceutical company’s stock valued at $29,182,000 after buying an additional 1,077,300 shares during the period. 50.10% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This article was reported by Ticker Report and is the property of of Ticker Report. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/3339825/valeant-pharmaceuticals-international-vrx-upgraded-to-neutral-at-mizuho.html.
About Valeant Pharmaceuticals International
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.